{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:21:10Z","timestamp":1791944470534,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104231"],"award-info":[{"award-number":["82104231"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.biopha.2024.117366","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:20:57Z","timestamp":1725376857000},"page":"117366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3\/AKT pathway and synergizes with PARP inhibitor"],"prefix":"10.1016","volume":"179","author":[{"given":"Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7381-5591","authenticated-orcid":false,"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2024.117366_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2024.117366_bib2","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"26","key":"10.1016\/j.biopha.2024.117366_bib3","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117366_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.56434\/j.arch.esp.urol.20237601.1","article-title":"Validity and future of primary androgen deprivation therapy in prostate cancer. integration in the era of new agents targeting the androgen receptor","volume":"76","author":"Carballido","year":"2023","journal-title":"Arch. Esp. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117366_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2013.08.008","article-title":"Castration-resistant prostate cancer: from new pathophysiology to new treatment","volume":"65","author":"Sridhar","year":"2014","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117366_bib6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.biopha.2024.117366_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","article-title":"Resistance to second-generation androgen receptor antagonists in prostate cancer","volume":"18","author":"Schmidt","year":"2021","journal-title":"Nat. Rev. Urol."},{"issue":"22","key":"10.1016\/j.biopha.2024.117366_bib8","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.biopha.2024.117366_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.biopha.2024.117366_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6004\/jnccn.2019.7307","article-title":"Germline and somatic mutations in prostate cancer for the clinician","volume":"17","author":"Cheng","year":"2019","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"2","key":"10.1016\/j.biopha.2024.117366_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/epi-2023-0045","article-title":"Epigenetics-based diagnostic and therapeutic strategies: shifting the paradigm in prostate cancer","volume":"15","author":"Clermont","year":"2023","journal-title":"Epigenomics"},{"issue":"7481","key":"10.1016\/j.biopha.2024.117366_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature12730","article-title":"N6-methyladenosine-dependent regulation of messenger RNA stability","volume":"505","author":"Wang","year":"2014","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.biopha.2024.117366_bib13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1101\/gad.262766.115","article-title":"RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation","volume":"29","author":"Yue","year":"2015","journal-title":"Genes Dev."},{"issue":"10","key":"10.1016\/j.biopha.2024.117366_bib14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","article-title":"Reading, writing and erasing mRNA methylation","volume":"20","author":"Zaccara","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117366_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","article-title":"Functions of N6-methyladenosine and its role in cancer","volume":"18","author":"He","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2024.117366_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115477","article-title":"N6-methyladenosine (m6A) in cancer therapeutic resistance: potential mechanisms and clinical implications","volume":"167","author":"Wang","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"7860","key":"10.1016\/j.biopha.2024.117366_bib17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.117366_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114118","article-title":"Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy","volume":"230","author":"Xu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2024.117366_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13046-023-02638-9","article-title":"METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy","volume":"42","author":"Sun","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2024.117366_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216122","article-title":"METTL3-m(6)A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma","volume":"559","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2024.117366_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41419-023-06411-w","article-title":"METTL3 facilitates renal cell carcinoma progression by PLOD2 m(6)A-methylation under prolonged hypoxia","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.biopha.2024.117366_bib22","doi-asserted-by":"crossref","first-page":"8852","DOI":"10.3390\/cimb45110555","article-title":"STM2457 inhibits the invasion and metastasis of pancreatic cancer by down-regulating BRAF-activated noncoding RNA N6-methyladenosine modification","volume":"45","author":"Hao","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117366_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12885-023-11741-1","article-title":"The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2024.117366_bib24","article-title":"Clinical and molecular significance of the RNA m(6)A methyltransferase complex in prostate cancer.","volume":"13","author":"Lothion-Roy","year":"2022","journal-title":"Front Genet."},{"key":"10.1016\/j.biopha.2024.117366_bib25","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70700","article-title":"Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer","volume":"12","author":"Wu","year":"2023","journal-title":"Elife"},{"issue":"16","key":"10.1016\/j.biopha.2024.117366_bib26","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1158\/0008-5472.CAN-19-4044","article-title":"FTO-dependent N (6)-Methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling","volume":"80","author":"Huang","year":"2020","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2024.117366_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13046-022-02581-1","article-title":"The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer","volume":"42","author":"Xu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"D1","key":"10.1016\/j.biopha.2024.117366_bib28","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","article-title":"The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences","volume":"50","author":"Perez-Riverol","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.biopha.2024.117366_bib29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jpha.2023.04.009","article-title":"Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer","volume":"13","author":"Xiao","year":"2023","journal-title":"J. Pharm. Anal."},{"issue":"5","key":"10.1016\/j.biopha.2024.117366_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrc3720","article-title":"IGF binding proteins in cancer: mechanistic and clinical insights","volume":"14","author":"Baxter","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.117366_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12373","article-title":"IGFBP3 and MAPK\/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer","volume":"62","author":"Mayo","year":"2017","journal-title":"J. Pineal Res"},{"issue":"3","key":"10.1016\/j.biopha.2024.117366_bib32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ijc.23100","article-title":"The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells","volume":"122","author":"Peng","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"20","key":"10.1016\/j.biopha.2024.117366_bib33","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/jnci\/djh286","article-title":"Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells","volume":"96","author":"Lee","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.biopha.2024.117366_bib34","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/2159-8290.CD-20-0163","article-title":"Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1\/2- and Non-BRCA1\/2-mutant cancers","volume":"10","author":"Yap","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2024.117366_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"3","key":"10.1016\/j.biopha.2024.117366_bib36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","article-title":"m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer","volume":"37","author":"Huang","year":"2020","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.biopha.2024.117366_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41571-023-00774-x","article-title":"The roles and implications of RNA m(6)A modification in cancer","volume":"20","author":"Deng","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.117366_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221122997","article-title":"METTL3-Mediated m(6)A modification of lncRNA MALAT1 facilitates prostate cancer growth by activation of PI3K\/AKT signaling","volume":"31","author":"Mao","year":"2022","journal-title":"Cell Transpl."},{"issue":"4","key":"10.1016\/j.biopha.2024.117366_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41419-023-05773-5","article-title":"Post-transcriptional modification of m(6)A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.biopha.2024.117366_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41419-023-05627-0","article-title":"RBM3 suppresses stemness remodeling of prostate cancer in bone microenvironment by modulating N6-methyladenosine on CTNNB1 mRNA","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.biopha.2024.117366_bib41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41419-022-04817-6","article-title":"METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2024.117366_bib42","article-title":"A novel M6A-related genes signature can impact the immune status and predict the prognosis and drug sensitivity of lung adenocarcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117366_bib43","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1078-0432.CCR-06-1217","article-title":"The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3","volume":"13","author":"Yin","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.117366_bib44","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5608","article-title":"CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3","volume":"64","author":"Zhong","year":"2024","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117366_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.108984","article-title":"IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer","volume":"27","author":"Leslie","year":"2024","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.biopha.2024.117366_bib46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.molcel.2020.06.017","article-title":"METTL3 and N6-methyladenosine promote homologous recombination-mediated repair of DSBs by modulating DNA-RNA hybrid accumulation","volume":"79","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2024.117366_bib47","article-title":"METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF\/RAD51 axis","volume":"11","author":"Li","year":"2022","journal-title":"Elife"},{"issue":"20","key":"10.1016\/j.biopha.2024.117366_bib48","doi-asserted-by":"crossref","first-page":"11629","DOI":"10.1093\/nar\/gkab460","article-title":"Human MettL3-MettL14 RNA adenine methyltransferase complex is active on double-stranded DNA containing lesions","volume":"49","author":"Yu","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.117366_bib49","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1021\/acs.jmedchem.2c01601","article-title":"METTL3 from target validation to the first small-molecule inhibitors: a medicinal chemistry journey","volume":"66","author":"Fiorentino","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2024.117366_bib50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12935-023-03096-1","article-title":"Therapeutic effect and transcriptome-methylome characteristics of METTL3 inhibition in liver hepatocellular carcinoma","volume":"23","author":"Liu","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"33","key":"10.1016\/j.biopha.2024.117366_bib51","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1038\/s41388-023-02760-0","article-title":"Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy","volume":"42","author":"Gao","year":"2023","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.biopha.2024.117366_bib52","doi-asserted-by":"crossref","first-page":"12738","DOI":"10.1021\/acs.jmedchem.1c00773","article-title":"1,4,9-Triazaspiro[5.5]undecan-2-one derivatives as potent and selective METTL3 inhibitors","volume":"64","author":"Dolbois","year":"2021","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.biopha.2024.117366_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205148","article-title":"The METTL3 RNA methyltransferase regulates transcriptional networks in prostate cancer","volume":"14","author":"Haigh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2024.117366_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-023-01477-7","article-title":"Methyltransferase-like proteins in cancer biology and potential therapeutic targeting","volume":"16","author":"Qi","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2024.117366_bib55","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1158\/2159-8290.CD-23-0007","article-title":"Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity","volume":"13","author":"Guirguis","year":"2023","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.biopha.2024.117366_bib56","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.it.2020.09.002","article-title":"Transcription factor Bhlhe40 in immunity and autoimmunity","volume":"41","author":"Cook","year":"2020","journal-title":"Trends Immunol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224012514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224012514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:25:37Z","timestamp":1784762737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224012514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":56,"alternative-id":["S0753332224012514"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117366","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3\/AKT pathway and synergizes with PARP inhibitor","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117366"}}